市場調查報告書

原發性硬化性膽管炎:至2030年的流行病學預測

Primary Sclerosing Cholangitis - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 955870
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
原發性硬化性膽管炎:至2030年的流行病學預測 Primary Sclerosing Cholangitis - Epidemiology Forecast to 2030
出版日期: 2020年07月01日內容資訊: 英文 80 Pages
簡介

本報告提供美國、德國、法國、義大利、西班牙、英國、日本的主要7個國家的至2030年的原發性硬化性膽管炎(PSC)的流行病學展望調查,SWOT分析,疾病的背景和概要,流行病學與患者數,各國流行病學,治療和管理,未支援的需求等資訊。

目錄

第1章 主要調查結果

第2章 摘要整理

第3章 SWOT分析

第4章 市場概要

  • 2017年的市場佔有率
  • 2030年的市場佔有率

第5章 疾病的背景和概要

  • 簡介
  • 病因
  • 徵兆與症狀
  • 危險因素與遺傳學
  • 臨床表現型
  • 病理生理學
    • PSC的免疫病理學
  • 關聯的疾病和併發症
  • 臨床表現
  • 診斷調查

第6章 流行病學和患者數

  • 主要調查結果
  • 主要7個國家的患者數
  • 前提和根據:主要7個國家

第7章 各國流行病學

  • 美國
    • 患者數
    • 盛行率
    • 併發症
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 治療和管理

  • 指南
    • American College of Gastroenterology的指南
    • AASLD的指南
    • British Society of Gastroenterology和UK-PSC的指南
  • 病人歷程
  • 案例研究
    • 美國的案例

第9章 未支援的需求

第10章 附錄

  • 調查手法

章11:DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0944

DelveInsight's 'Primary Sclerosing Cholangitis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Primary Sclerosing Cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Primary Sclerosing Cholangitis : Understanding

The DelveInsight's Primary Sclerosing Cholangitis epidemiology report gives a thorough understanding of the Primary Sclerosing Cholangitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Sclerosing Cholangitis in the US and Europe. Moreover, the report covers the detailed information of the Primary Sclerosing Cholangitis epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight

This section encompassing Primary Sclerosing Cholangitis epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Sclerosing Cholangitis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation

The Primary Sclerosing Cholangitis epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Primary Sclerosing Cholangitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Primary Sclerosing Cholangitis report and model provide an overview of the global trends of Primary Sclerosing Cholangitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Primary Sclerosing Cholangitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Primary Sclerosing Cholangitis.
  • The report provides the segmentation of the Primary Sclerosing Cholangitis epidemiology

Report Highlights:

  • 11-year Forecast of Primary Sclerosing Cholangitis Epidemiology
  • 7MM Coverage
  • Prevalent cases of Primary Sclerosing Cholangitis
  • Prevalence of Primary Sclerosing Cholangitis by gender
  • Comorbidities associated with Primary Sclerosing Cholangitis

KOL Views

We interview KOLs and include SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Primary Sclerosing Cholangitis?
  • What are the key findings pertaining to the Primary Sclerosing Cholangitis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Primary Sclerosing Cholangitis across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of Primary Sclerosing Cholangitis?
  • What are the currently available treatments of Primary Sclerosing Cholangitis?

Reasons to buy:

The Primary Sclerosing Cholangitis Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Primary Sclerosing Cholangitis market.
  • Quantify patient populations in the global Primary Sclerosing Cholangitis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Primary Sclerosing Cholangitis therapeutics in each of the markets covered
  • Understand the magnitude of Primary Sclerosing Cholangitis population by its epidemiology
  • The Primary Sclerosing Cholangitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1 Key Insights

2 Executive Summary of Primary Sclerosing Cholangitis

3 SWOT Analysis for Primary Sclerosing Cholangitis

4 Primary Sclerosing Cholangitis Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of PSC in 2017
  • 4.2 Market Share (%) Distribution of PSC in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Etiology
  • 5.3 Signs and Symptoms
  • 5.4 Risk Factors and genetics
  • 5.5 Clinical Phenotypes
  • 5.6 Pathophysiology
    • 5.6.1 Immunopathology of PSC
  • 5.7 Associated Diseases and Complications
  • 5.8 Clinical Presentation
  • 5.9 Diagnostic Investigations

Cancer surveillance in PSC

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Total Prevalent Population of Primary Sclerosing Cholangitis in 7MM
  • 6.3 Assumption and Rationale: 7MM

7 Country Wise-Epidemiology of Primary Sclerosing Cholangitis

  • 7.1 The United States
    • 7.1.1 Prevalent cases of Primary Sclerosing Cholangitis in the United States
    • 7.1.2 Prevalence of Primary Sclerosing Cholangitis by Gender in the United States
    • 7.1.3 Comorbidities associated with Primary Sclerosing Cholangitis in the United States
  • 7.2 Germany
    • 7.2.1 Prevalent cases of Primary Sclerosing Cholangitis in Germany
    • 7.2.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Germany
    • 7.2.3 Comorbidities associated with Primary Sclerosing Cholangitis in Germany
  • 7.3 France
    • 7.3.1 Prevalent cases of Primary Sclerosing Cholangitis in France
    • 7.3.2 Prevalence of Primary Sclerosing Cholangitis by Gender in France
    • 7.3.3 Comorbidities associated with Primary Sclerosing Cholangitis in France
  • 7.4 Italy
    • 7.4.1 Prevalent cases of Primary Sclerosing Cholangitis in Italy
    • 7.4.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Italy
    • 7.4.3 Comorbidities associated with Primary Sclerosing Cholangitis in Italy
  • 7.5 Spain
    • 7.5.1 Prevalent cases of Primary Sclerosing Cholangitis in Spain
    • 7.5.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Spain
    • 7.5.3 Comorbidities associated with Primary Sclerosing Cholangitis in Spain
  • 7.6 The United Kingdom
    • 7.6.1 Prevalent cases of Primary Sclerosing Cholangitis in the UK
    • 7.6.2 Prevalence of Primary Sclerosing Cholangitis by Gender in the UK
    • 7.6.3 Comorbidities associated with Primary Sclerosing Cholangitis in the UK
  • 7.7 Japan
    • 7.7.1 Prevalent cases of Primary Sclerosing Cholangitis in Japan
    • 7.7.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Japan
    • 7.7.3 Comorbidities associated with Primary Sclerosing Cholangitis in Japan

8 Treatment and Management

  • 8.1 Guidelines
    • 8.1.1 American College of Gastroenterology Guidelines
    • 8.1.2 AASLD Guidelines for treatment and management of PSC
    • 8.1.3 British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
  • 8.2 Patient Journey
  • 8.3 Case study
    • 8.3.1 Primary Sclerosing Cholangitis: As case Discussion in the US

9 Unmet Needs

10 Appendix

  • 10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Summary of Primary sclerosing cholangitis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Phenotypic variants of primary sclerosing cholangitis: Terms and features
  • Table 3: Total cases of Primary Sclerosing Cholangitis in 7MM (2017-2030)
  • Table 4: Prevalent cases of Primary Sclerosing Cholangitis in the United States (2017-2030)
  • Table 5: Prevalence of Primary Sclerosing Cholangitis by Gender in the United States (2017-2030)
  • Table 6: Comorbidities associated with PSC in the United States (2017-2030)
  • Table 7: Prevalent cases of Primary Sclerosing Cholangitis in Germany (2017-2030)
  • Table 8: Prevalence of Primary Sclerosing Cholangitis by Gender in Germany (2017-2030)
  • Table 9: Comorbidities associated with PSC in Germany (2017-2030)
  • Table 10: Prevalent cases of Primary Sclerosing Cholangitis in France (2017-2030)
  • Table 11: Prevalence of Primary Sclerosing Cholangitis by Gender in France (2017-2030)
  • Table 12: Comorbidities associated with PSC in France (2017-2030)
  • Table 13: Prevalent cases of Primary Sclerosing Cholangitis in Italy (2017-2030)
  • Table 14: Prevalence of Primary Sclerosing Cholangitis by Gender in Italy (2017-2030)
  • Table 15: Comorbidities associated with PSC in Italy (2017-2030)
  • Table 16: Prevalent cases of Primary Sclerosing Cholangitis in Spain (2017-2030)
  • Table 17: Prevalence of Primary Sclerosing Cholangitis by Gender in Spain (2017-2030)
  • Table 18: Comorbidities associated with PSC in Spain (2017-2030)
  • Table 19: Prevalent cases of Primary Sclerosing Cholangitis in the UK (2017-2030)
  • Table 20: Prevalence of Primary Sclerosing Cholangitis by Gender in the UK (2017-2030)
  • Table 21: Comorbidities associated with PSC in the UK (2017-2030)
  • Table 22: Prevalent cases of Primary Sclerosing Cholangitis in Japan (2017-2030)
  • Table 23: Prevalence of Primary Sclerosing Cholangitis by Gender in Japan (2017-2030)
  • Table 24: Comorbidities associated with PSC in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Pathophysiology of Primary sclerosing cholangitis
  • Figure 3: Cholangiocarcinoma surveillance in patients with primary sclerosing cholangitis
  • Figure 4: Cholangiocarcinoma surveillance in patients with primary sclerosing cholangitis
  • Figure 5: Total prevalent cases of Primary Sclerosing Cholangitis in 7MM (2017-2030)
  • Figure 6: Prevalent cases of Primary Sclerosing Cholangitis in the United States (2017-2030)
  • Figure 7: Prevalence of Primary Sclerosing Cholangitis by Gender in the United States(2017-2030)
  • Figure 8: Comorbidities associated with PSC in the United States (2017-2030)
  • Figure 9: Prevalent cases of Primary Sclerosing Cholangitis in Germany (2017-2030)
  • Figure 10: Prevalence of Primary Sclerosing Cholangitis by Gender in Germany (2017-2030)
  • Figure 11: Comorbidities associated with PSC in Germany (2017-2030)
  • Figure 12: Prevalent cases of Primary Sclerosing Cholangitis in France (2017-2030)
  • Figure 13: Prevalence of Primary Sclerosing Cholangitis by Gender in France (2017-2030)
  • Figure 14: Comorbidities associated with PSC in France (2017-2030)
  • Figure 15: Prevalent cases of Primary Sclerosing Cholangitis in Italy (2017-2030)
  • Figure 16: Prevalence of Primary Sclerosing Cholangitis by Gender in Italy (2017-2030)
  • Figure 17: Comorbidities associated with PSC in Italy (2017-2030)
  • Figure 18: Prevalent cases of Primary Sclerosing Cholangitis in Spain (2017-2030)
  • Figure 19: Prevalence of Primary Sclerosing Cholangitis by Gender in Spain (2017-2030)
  • Figure 20: Comorbidities associated with PSC in Spain (2017-2030)
  • Figure 21: Prevalent cases of Primary Sclerosing Cholangitis in the UK (2017-2030)
  • Figure 22: Prevalence of Primary Sclerosing Cholangitis by Gender in the UK (2017-2030)
  • Figure 23: Comorbidities associated with PSC in the UK (2017-2030)
  • Figure 24: Prevalent cases of Primary Sclerosing Cholangitis in Japan (2017-2030)
  • Figure 25: Prevalence of Primary Sclerosing Cholangitis by Gender in Japan (2017-2030)
  • Figure 26: Comorbidities associated with PSC in Japan (2017-2030)
  • Figure 27: Patient Journey for PSC
  • Figure 28: Unmet needs of PSC